BioCentury
ARTICLE | Clinical News

Watchman: Phase II/III data

April 6, 2009 7:00 AM UTC

In the open-label, international Phase II/III PROTECT AF trial in 707 patients, Watchman plus warfarin produced a non-inferior 32% reduction in the primary efficacy endpoint of all stroke, CV and unex...